Solventum Corporation (SOLV) Debt to Equity Ratio: 1.00
Is Solventum Corporation’s debt to equity ratio high or low?
Solventum Corporation's debt to equity ratio of 1.00 is 36% above its 5-year average of 0.74, around the middle of its 5-year range (0.00–2.71).
As of Friday, June 12, 2026. 46.09% below its 12-month average of 1.85.
SOLV Debt to Equity Ratio Chart
SOLV Average Debt to Equity Ratio Chart
SOLV Current vs Average Debt to Equity Ratio Chart
SOLV Debt to Equity Ratio Metrics
DEBT TO EQUITY RATIO
1.00
DEBT TO EQUITY RATIO AVG TTM
1.85
DEBT TO EQUITY RATIO AVG 3Y
1.10
DEBT TO EQUITY RATIO AVG 5Y
0.74
DEBT TO EQUITY RATIO AVG 10Y
0.74
DEBT TO EQUITY RATIO AVG 15Y
0.74
DEBT TO EQUITY RATIO AVG 20Y
0.74
CURRENT VS TTM AVG
-46.09%
CURRENT VS 3Y AVG
-9.50%
CURRENT VS 5Y AVG
+35.75%
CURRENT VS 10Y AVG
+35.75%
CURRENT VS 15Y AVG
+35.75%
CURRENT VS 20Y AVG
+35.75%
SOLV Competitors' Debt to Equity Ratio
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Solventum Corporation (SOLV) | $13.72B | 1.00 | 1.85 | 1.10 | 0.74 |
| Align Technology, Inc. (ALGN) | $12.27B | 0.03 | 0.03 | 0.03 | 0.03 |
| Baxter International Inc. (BAX) | $10.58B | 1.63 | 1.78 | 2.05 | 1.83 |
| Hologic, Inc. (HOLX) | $16.97B | 0.52 | 0.52 | 0.55 | 0.69 |
| Charles River Laboratories International, Inc. (CRL) | $8.94B | 0.97 | 0.88 | 0.91 | 0.99 |
| Moderna, Inc. (MRNA) | $18.71B | 0.22 | 0.15 | 0.11 | 0.10 |
| Tempus AI, Inc. (TEM) | $8.65B | 1.66 | 4.99 | 4.99 | 4.99 |
| Bio-Rad Laboratories, Inc. (BIO) | $7.92B | 0.21 | 0.21 | 0.18 | 0.13 |
| Hims & Hers Health, Inc. (HIMS) | $6.19B | 2.34 | 1.18 | 0.60 | 0.40 |
| BioNTech SE (BNTX) | $22.39B | 0.01 | 0.01 | 0.01 | 0.04 |
Financial Health
Debt/Equity
1.00
Current Ratio
1.23
Solventum Corporation Debt to Equity Ratio Formula & Definition
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Solventum Corporation Debt to Equity Ratio FAQ
- What is the debt to equity ratio for Solventum Corporation (SOLV)?
- The debt to equity ratio for SOLV stock is 1.00.
- Is Solventum Corporation's debt to equity ratio high or low?
- Solventum Corporation's debt to equity ratio of 1.00 is 36% above its 5-year average of 0.74, around the middle of its 5-year range (0.00–2.71).
- What is the TTM average debt to equity ratio for Solventum Corporation (SOLV)?
- The TTM average debt to equity ratio for SOLV stock is 1.85.
- What is the 3Y average debt to equity ratio for Solventum Corporation (SOLV)?
- The 3Y average debt to equity ratio for SOLV stock is 1.10.
- What is the 5Y average debt to equity ratio for Solventum Corporation (SOLV)?
- The 5Y average debt to equity ratio for SOLV stock is 0.74.
- What is the 10Y average debt to equity ratio for Solventum Corporation (SOLV)?
- The 10Y average debt to equity ratio for SOLV stock is 0.74.
- What is the 15Y average debt to equity ratio for Solventum Corporation (SOLV)?
- The 15Y average debt to equity ratio for SOLV stock is 0.74.
- What is the 20Y average debt to equity ratio for Solventum Corporation (SOLV)?
- The 20Y average debt to equity ratio for SOLV stock is 0.74.
Solventum Corporation Debt to Equity Ratio History
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2025-12-31 | 1.00 |
| 2024-12-31 | 2.71 |
| 2023-12-31 | 0.71 |
| 2022-12-31 | 0.00 |
| 2021-12-31 | 0.00 |
| 2020-12-31 | 0.00 |
Related Metrics
About Solventum Corporation
Solventum Corporation, established in 2023 and headquartered in Saint Paul, Minnesota, operates as a healthcare entity dedicated to pioneering, producing, and commercializing diverse solutions that address critical needs for both customers and patients. The company's business activities are organized into four principal segments. The Medsurg division furnishes various products and services, including sophisticated wound care items, intravenous (I.V.) site management tools, sterilization assurance systems, temperature regulation devices, surgical instruments, stethoscopes, and medical electrodes. Its Dental Solutions segment provides a comprehensive range of dental and orthodontic offerings, such as brackets, clear aligners, restorative filling materials, and bonding agents. The Health Information Systems division concentrates on advanced software platforms, covering functionalities like computer-assisted physician documentation, direct billing and coding automation, classification frameworks, voice recognition capabilities, and data visualization tools. Finally, the Purification and Filtration segment supplies an array of purification and filtration technologies, including various filters, purifiers, cartridges, and specialized membranes.
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- CEO
- Bryan C. Hanson